Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:KURA NASDAQ:LXEO NASDAQ:ORKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.42-0.3%$7.55$5.90▼$29.61$543.06M2.221.84 million shs1.47 million shsKURAKura Oncology$6.02-0.5%$6.17$5.41▼$21.57$523.78M0.411.24 million shs1.19 million shsLXEOLexeo Therapeutics$4.61-2.5%$3.99$1.45▼$13.63$157.02M1.35462,100 shs552,822 shsORKAOruka Therapeutics$13.60+0.1%$12.82$5.49▼$52.32$508.82M-0.35159,251 shs142,850 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-0.27%-5.36%-6.08%-3.89%-73.03%KURAKura Oncology-0.50%-3.37%+3.61%-6.96%-71.07%LXEOLexeo Therapeutics-2.54%+11.62%+5.25%-0.65%-63.27%ORKAOruka Therapeutics+0.07%-4.56%+7.85%+26.98%+1,359,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.4814 of 5 stars4.32.00.00.02.32.51.3KURAKura Oncology3.3434 of 5 stars3.41.00.04.70.60.80.6LXEOLexeo Therapeutics2.5704 of 5 stars3.51.00.00.03.12.50.6ORKAOruka Therapeutics2.2738 of 5 stars3.60.00.00.01.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$20.29173.44% UpsideKURAKura Oncology 2.86Moderate Buy$24.50306.98% UpsideLXEOLexeo Therapeutics 3.00Buy$17.17272.38% UpsideORKAOruka Therapeutics 3.20Buy$40.38196.88% UpsideCurrent Analyst Ratings BreakdownLatest LXEO, KURA, ORKA, and ARVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/31/2025LXEOLexeo TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.007/23/2025ORKAOruka TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.007/21/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.006/26/2025KURAKura OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight6/20/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.006/4/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.006/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/30/2025LXEOLexeo TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $10.005/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M2.06N/AN/A$8.17 per share0.91KURAKura Oncology$53.88M9.67N/AN/A$5.32 per share1.13LXEOLexeo Therapeutics$650K235.46N/AN/A$3.53 per share1.31ORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%8/6/2025 (Estimated)KURAKura Oncology-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%8/7/2025 (Estimated)LXEOLexeo Therapeutics-$98.33M-$3.30N/AN/AN/AN/A-85.86%-68.48%8/11/2025 (Estimated)ORKAOruka Therapeutics-$83.72M-$4.51N/AN/AN/AN/A-25.66%-23.39%8/7/2025 (Estimated)Latest LXEO, KURA, ORKA, and ARVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025LXEOLexeo Therapeutics-$0.61N/AN/AN/AN/AN/A8/7/2025Q2 2025KURAKura Oncology$0.15N/AN/AN/A$64.95 millionN/A8/7/2025Q1 2025ORKAOruka Therapeutics-$0.48N/AN/AN/AN/AN/A8/6/2025Q2 2025ARVNArvinas-$0.87N/AN/AN/A$34.42 millionN/A5/14/2025Q1 2025ORKAOruka Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/A5/12/2025Q1 2025LXEOLexeo Therapeutics-$0.80-$0.99-$0.19-$0.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.584.58KURAKura Oncology0.028.078.07LXEOLexeo Therapeutics0.013.423.42ORKAOruka TherapeuticsN/A30.0330.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%KURAKura OncologyN/ALXEOLexeo Therapeutics60.67%ORKAOruka Therapeutics56.44%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%KURAKura Oncology6.40%LXEOLexeo Therapeutics5.30%ORKAOruka Therapeutics24.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million69.54 millionOptionableKURAKura Oncology13086.57 million81.03 millionOptionableLXEOLexeo Therapeutics5833.20 million31.44 millionNot OptionableORKAOruka TherapeuticsN/A37.44 million28.20 millionN/ALXEO, KURA, ORKA, and ARVN HeadlinesRecent News About These CompaniesOruka Therapeutics (ORKA) Expected to Announce Earnings on ThursdayJuly 31 at 4:18 AM | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from HC WainwrightJuly 23, 2025 | marketbeat.comOruka Therapeutics' (ORKA) Outperform Rating Reaffirmed at WedbushJuly 23, 2025 | americanbankingnews.comOruka Therapeutics stock rises after FDA clears IND for psoriasis drugJuly 22, 2025 | investing.comOruka Therapeutics Shares Climb After FDA Greenlights Psoriasis Drug TrialJuly 22, 2025 | msn.comWedbush Reiterates Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA)July 21, 2025 | marketbeat.comOruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in SeptemberJuly 21, 2025 | globenewswire.comOruka Therapeutics (NASDAQ:ORKA) Shares Down 6.8% - Time to Sell?July 19, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Buy" from AnalystsJuly 15, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Shares Up 7.4% - What's Next?July 7, 2025 | marketbeat.comOruka Therapeutics Announces Promotion of Laura Sandler to Oper Chief >ORKAJuly 3, 2025 | marketwatch.comOruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating OfficerJuly 1, 2025 | globenewswire.comORKA Oruka Therapeutics, Inc.May 30, 2025 | seekingalpha.comH.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 TrialMay 27, 2025 | insidermonkey.comOruka Therapeutics begins trial for psoriasis treatmentMay 21, 2025 | uk.investing.comOruka Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 21, 2025 | globenewswire.comOruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F AntibodyMay 20, 2025 | globenewswire.comTD Cowen Remains a Buy on Oruka Therapeutics (ORKA)May 17, 2025 | theglobeandmail.comWedbush Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)May 17, 2025 | theglobeandmail.comOruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comOruka Therapeutics to Present at Bank of America Securities 2025 Health Care ConferenceApril 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXEO, KURA, ORKA, and ARVN Company DescriptionsArvinas NASDAQ:ARVN$7.42 -0.02 (-0.27%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.42 +0.00 (+0.07%) As of 08/1/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Kura Oncology NASDAQ:KURA$6.02 -0.03 (-0.50%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.02 0.00 (-0.08%) As of 08/1/2025 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Lexeo Therapeutics NASDAQ:LXEO$4.61 -0.12 (-2.54%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.66 +0.04 (+0.98%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Oruka Therapeutics NASDAQ:ORKA$13.60 +0.01 (+0.07%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.60 0.00 (0.00%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
